🇺🇸 FDA
Pipeline program

Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects

CLI-06795AA1-09

Phase 1 other active

Quick answer

Evaluation of the effect of CHF6795 on the pharmacokinetics of midazolam, repaglinide and rosuvastatin in healthy subjects for Chronic cough is a Phase 1 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).

Program details

Company
Chiesi Farmaceutici S.p.A
Indication
Chronic cough
Phase
Phase 1
Modality
other
Status
active

Clinical trials